PCSK9 inhibitor experiences and preferences of patients and healthcare professionals in decision-making: A mixed methods study
For patients and HCPs, efficacy was the most important aspect in choosing a PCSK9i. Even though shared decision-making is recommended by the guidelines and preferred by patients, in clinical practice only a minority of the HCPs apply this. To facilitate shared decision-making, future research should investigate the development and impact of a decision aid for patients.
Authors
- Leonieke W. Kranenburg (ORCID: https://orcid.org/0000-0001-5941-1056)
- Jeanine E. Roeters van Lennep (ORCID: https://orcid.org/0000-0001-6870-9962)
- Ken Redekop (ORCID: https://orcid.org/0000-0001-9538-4083)
- Janneke W.C.M. Mulder (ORCID: https://orcid.org/0009-0003-9837-726X)
- Annette M.H. Galema‐Boers
Institutions
- Erasmus MC (NL)
- Erasmus MC Cancer Institute (NL)
- Erasmus University Rotterdam (NL)
Publication Details
- Journal
- Atherosclerosis
- Published
- 2024-12-20
- DOI
- https://doi.org/10.1016/j.atherosclerosis.2024.119101
- Citations
- 2
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 1.15
Funders
- Novartis
- Erasmus Medisch Centrum